Newsletter 05
June 06 2007
May at a glance
In May the main objective has been to complete the development of rat NGAL antibodies in readiness for launching these on the market. In addition, a lot of work has gone into completing the prospectus for the share issue. just as the Board will thereafter be ready with suggestions regarding its future composition. May has also seen the appointment of new staff. The company was represented at the annual meeting of the Danish Immunological Society, and two PCT-patent applications have been submitted on further diagnostic applications of NGAL and Gc-globulin.
